News

The closing of the financing is expected to occur within five business days. HPPI will use this funding to immediately accelerate its development program, which is focused on

DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).

PXS4728A is a Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) Inhibitor discovered by Pharmaxis that works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes. Pharmaxis has developed

The primary objectives of COPD treatment are to enable patients to effectively manage their disease, improve their health status (measured by the St George’s Respiratory Questionnaire (SGRQ)) and

The company said that the new Berinert 1500 IU format is reconstituted with 3mL vial of Sterile Water for Injection (Diluent). In Canada, Berinert is indicated to treat

Safinamide is a new chemical entity and it has unique mode of action including selective and reversible MAO-B-inhibition and blocking of voltage dependent sodium channels which leads to

The drug is indicated for NSCLC patients who have failed two prior lines of therapy to show a clinically important and statistically robust improvement in overall survival over

The approval marks the first approved combination and first approved sumatriptan migraine product for patients aged 12-17 years. The company said that the two medicines sumatriptan and naproxen

ALN-AAT is a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT). The company said that ALN-AAT employs its Enhanced Stabilization Chemistry (ESC)-GalNAc delivery technology. The proposed clinical